Preterm labor occurs in 8 to 10 percent of all births. Despite various strategies to reduce this percentage, it has remained relatively stable. Diagnosing preterm birth is difficult and has a high false-positive rate. As a result, many women are needlessly hospitalized, miss work or restrict their activies. The fetal fibronectin test could potentially reduce the need for hospitalizations by more accurately diagnosing preterm labor and providing peace of mind to women.
The story perpetuates fear of preterm birth among asymptomatic women by focusing on only a small part of the preterm labor population and by not distinguishing the risk of preterm labor in asymptomatic versus symptomatic women. The test is really intended for and is only useful in symptomatic women, not as a screening test in women without symptoms.
Furthermore, the story does not comment on the strength of the available evidence to support the use of the test. Specifically, the story does not comment on whether we know if the use of the test will result in better outcomes, such as reduced hospitalizations or prevention of preterm birth. The story does not quantify the benefits of the test. The simple question, how many hospitlizations could be prevented?, is not answered.
Finally, the story does not really comment on the harms, or potential harms of the test. For example, the story could have commented on hte possible consequences of a false negative or false positive test result. Simply stating that "no test is perfect" is not sufficient.
The story mentions the cost of the test and comments that most insurance companies cover it, however it is not clear if insurance companies will cover it in asymptomatic women.
The story does not quantify the benefits of the test. How many hospitalizations could be prevented?
The story does not really comment on the harms, or potential harms of the test. For example, the story could have commented on hte possible consequences of a false negative or false positive test result. Simply stating that "no test is perfect" is not sufficient.
The story does not comment on the strength of the available evidence to support the use of the test. Specifically, the story does not comment on whether we know if the use of the test will result in better outcomes, such as reduced hospitalizations or prevention of preterm birth.
The story perpetuates fear of preterm birth among asymptomatic women by focusing on only a small part of the preterm labor population and by not distinguishing the risk of preterm labor in asymptomatic versus symptomatic women. The test is really intended for and is only useful in symptomatic women, not as a screening test in women without symptoms.
The story quotes multiple experts.
The story mentions examination of the cervix as the alternative for diagnosing preterm labor but could have also mentioned ultrasonography.
The story describes how widely available the test is.
Clearly the test is not new.
Because the story quotes mulitple experts, the reader can assume that the story does not rely on a press release as the sole source of information.
Systematic, Criteria-Driven
Take all the issues enmeshed in any cancer screening story and amplify it with the liquid biopsy issue. @AP's @CarlaKJohnson. did a solid job here. https://apnews.com/article/science-business-health-hodgkin-lymphoma-oregon-ca899bb9c4c7f1859d4e9ce16a1cf78d
Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like